Neuropathological characteristics of progression after prolonged response to bevacizumab in multifocal hemangioblastoma.

Abstract

BACKGROUND:

Antiangiogenic treatment has been explored in few patients with hemangioblastoma after failure of surgery and radiotherapy.

CASE REPORT:

We present the first histopathological follow-up study of a bevacizumab-responsive hemangioblastoma that eventually progressed. For a period of 12 months, therapy with bevacizumab achieved a clinical response and radiological stabilization in a patient with progressive multifocal central nervous system (CNS) hemangioblastoma. Subsequently, selected tumor sites showed radiological progression, in particular, the formation of an intramedullary lesion of the initially predominantly leptomeningeal disease. Histology showed diffuse dural invasion by the hemangioblastoma accompanied with a relatively reduced cell density compared to the preserved vessel structures.

CONCLUSION:

The pattern of progression upon vascular endothelial growth factor (VEGF)-targeting antiangiogenic treatment in hemangioblastoma may involve increased tumor invasiveness.

• Authors: Katharina Seystahl, Michael Weller, Oliver Bozinov, Regina Reimann, Elisabeth Rushing
• Journal: Oncology research and treatment (Oncol Res Treat) Vol. 37 Issue 4 Pg. 209-12 ( 2014) ISSN: 2296-5262 [Electronic] Switzerland
• PMID: 24732646 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2014 S. Karger GmbH, Freiburg.

Chemical References

• Angiogenesis Inhibitors
• Antibodies, Monoclonal, Humanized
• Bevacizumab

Topics

• Aged
• Angiogenesis Inhibitors (therapeutic use)
• Antibodies, Monoclonal, Humanized (therapeutic use)
• Bevacizumab
• Brain Neoplasms (drug therapy, pathology)
• Disease Progression
• Hemangioblastoma (drug therapy, pathology)
• Humans
• Longitudinal Studies
• Male
• Neoplasm Invasiveness
• Neoplasm Recurrence, Local (pathology, prevention & control)
• Spinal Cord Neoplasms (drug therapy, pathology)
• Treatment Outcome